118 results found
    1. Cancer Biology
    2. Immunology and Inflammation

    The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy

    Aaron R Lim et al.
    Diverse components of the tumor microenvironment affect T cell metabolism in ways that are crucial to improving immunotherapy.
    1. Cancer Biology
    2. Physics of Living Systems

    Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

    Xin Cui et al.
    A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.
    1. Cancer Biology
    2. Immunology and Inflammation

    Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy

    Shuhong Qi et al.
    Tregs form an "immunosuppressive ring" around solid tumors that is broken down during adoptive cell therapy and cyclophosphamide combination immunotherapy.
    1. Cancer Biology
    2. Genetics and Genomics

    Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction

    Shixiang Wang et al.
    Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.
    1. Immunology and Inflammation

    Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

    Rhoanne C McPherson et al.
    Peptide immunotherapy in mice depends upon sustained expression of co-inhibitory protein PD-1 in T cells.
    1. Cancer Biology
    2. Immunology and Inflammation

    SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint

    Emma Hajaj et al.
    SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.
    1. Biochemistry and Chemical Biology

    Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes

    Cristian A Lasagna-Reeves et al.
    Building on previous work (Lasagna-Reeves et al., 2015) it is shown that polyglutamine ATXN1 oligomers propagate locally in SCA1 mice, and that passive immunotherapy targeting soluble oligomers can lead to an improvement in motor coordination and a modest increase in life span.
    1. Cancer Biology
    2. Immunology and Inflammation

    Domain-swapped T cell receptors improve the safety of TCR gene therapy

    Michael T Bethune et al.
    Engineered T cell receptors enable targeted immunotherapy with a reduced risk of harmful autoimmunity.
    1. Immunology and Inflammation

    Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α

    Liku B Tezera et al.
    Immune checkpoint inhibition therapy for cancer paradoxically activates tuberculosis infection, and advanced human cell culture modelling demonstrates excess TNF-α section is the primary driver.
    1. Cancer Biology

    Cancer Immunotherapy: A peptide puzzle

    Jian Guan, Nilabh Shastri
    Why does cancer develop in situations where the immune system is perfectly capable of eliminating it?
    Insight
    Available as:
    • HTML
    • PDF

Refine your results by:

Type
Research categories